Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors

描述（由申请人提供）：加州大学有超过1200万癌症幸存者。癌症幸存者和了解癌症治疗的晚期效应是一个高度优先的领域。强大的SWOG临床试验数据库与医疗保险索赔数据的联系提供了一个独特的机会来评估治疗的后期效果，并可能建立一种机制来识别临床试验随访结束后治疗组之间的结果差异。我们建议使用一个数据库，该数据库将参加SWOG临床治疗和预防试验的患者联系起来，其中详细信息包括人口统计学，肿瘤细节，预后因素，临床因素，治疗类型（静脉注射，皮下注射和口服）和剂量，治疗期间的短期毒性，复发和生存结果与医疗保险索赔数据(基于ICD-9， HCPCS，和CPT代码)，这些代码可以提供长期随访，包括潜在疾病、合并症、新诊断、后续治疗、住院以及与治疗相关的费用/资源利用。的具体目的

DESCRIPTION (provided by applicant): There are over 12 million cancer survivors in the UC. Cancer survivorship and understanding late effects of cancer therapy is a high priority area. The linkage of the powerful SWOG clinical trial database to Medicare claims data provides a unique opportunity to evaluate late effects of therapy, and may establish a mechanism for identifying differences in outcomes between treatment groups after the clinical trial follow-up ends. We propose to use a database that has linked patients enrolled on SWOG clinical treatment and prevention trials where detailed information on demographics, tumor details, prognostic factors, clinical factors, treatment type (intravenous, subcutaneous and oral) and dose received, short term toxicities during the treatment period, recurrence and survival outcomes are captured with Medicare claims data (based on ICD-9, HCPCS, and CPT codes) which can provide long-term follow-up with underlying illnesses, comorbid conditions, new diagnoses, subsequent treatment, hospitalizations and costs/resource utilization associated with treatment. For the specific aims of our proposal, we will use the SWOG-Medicare linked database to determine the long term cardiovascular, hematologic, gastrointestinal, renal, endocrinologic and neurologic complications of (a) patients with prostate cancer randomized to continuous vs intermittent androgen deprivation (b) patients with prostate cancer treated with and without androgen deprivation (c) patients with breast and prostate cancer treated with and without taxanes (d) patients with non-small cell lung cancer treated with and without platinum agents (e) patients with pelvic cancer treated with chemotherapy and radiation vs. radiation alone. For each of these sub-aims, we will examine how these complications vary by pre-existing co-morbidities, such as diabetes and hypertension, as well as clinical and demographic factors, and examine the relationship between short term toxicities assessed during therapy on a clinical trial, as characterized by the Common Toxicity Criteria (CTC-AE), and long-term toxicities. Using the unique and valuable linked Medicare claims database with the NCI clinical trials database of the Southwest Oncology Group, we can perform analyses that overcome limitations of previously conduced population based research that utilized the SEER-Medicare database alone. If we can better predict who is at greatest risk for late toxicity, and who is not, we can improve long term outcomes for the growing population of cancer survivors